Seasonal Variation in Skin Cancer Diagnosis.

Front Public Health

Public Health Section, Department of Experimental Medicine, University of Perugia, Perugia, Italy; Umbrian Population Cancer Registry, Regional Government of Umbria, University of Perugia, Perugia, Italy.

Published: May 2016

Purpose: Seasonality of skin cancer is well known, and it is influenced by a number of variables, such as exposure and personal characteristics, but also health service factors. We investigated the variations in the diagnosis melanoma skin cancer (MSC) and non-melanoma skin cancer (NMSC) during the year.

Methods: We analyzed incident cases recorded in the Umbria Regional Cancer registry from 1994 to 2010 (1745 cases of MSC, 50% females, and 15,992 NMSC, 41% females). The Walter-Elwood test was used to assess seasonal effects. Relative risks were analyzed using negative binomial regression and splines.

Results: Seasonality of MSC and NMSC was similar. Incidence peaks were observed in weeks 8, 24, and 43 (February, July, and October) and troughs in weeks 16, 32, 52, and 1 (August and December). Both NMSC and MSC cancers showed most elevated risks in autumn. A seasonal effect was present for trunk (p < 0.001) and absent for face cancers (p = 0.3).

Conclusion: The observed pattern of diagnoses presumably depends on health service factors (e.g., organization of melanoma days, reduced access to care in August and during Christmas holidays) and personal factors (e.g., unclothing in the summer and delays in seeking care). High incidence rates in autumn could also in part depend on a late cancer progression effect of UV exposure. More efforts should be placed in order to guarantee uniform access to care through the year.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4848301PMC
http://dx.doi.org/10.3389/fpubh.2016.00078DOI Listing

Publication Analysis

Top Keywords

skin cancer
16
cancer
5
seasonal variation
4
skin
4
variation skin
4
cancer diagnosis
4
diagnosis purpose
4
purpose seasonality
4
seasonality skin
4
cancer well
4

Similar Publications

Background: Immune checkpoint inhibitors (ICIs) have been widely applicated for the treatment of patients with advanced esophageal cancer. Skin-related adverse reactions are frequent with ICIs, with toxic epidermal necrolysis (TEN) being a severe and potentially life-threatening cutaneous reaction.

Case Presentation: We present a case of a 70-year-old male with locally advanced esophageal cancer who developed severe toxic epidermal necrolysis (TEN) after 18 days of tislelizumab combined with chemotherapy.

View Article and Find Full Text PDF

Background: Melanoma is the fourth leading cause of cancer-related death worldwide. The continuous exploration and reporting of risk factors of melanoma is important for standardizing and reducing the incidence of the disease. Calcium signaling is a promising therapeutic target for melanoma; however, the relationship between total serum calcium levels and melanoma development remains unclear.

View Article and Find Full Text PDF

Cutaneous melanoma is the deadliest form of skin cancer. Despite advancements in treatment, many patients still face poor outcomes. A deeper understanding of the mechanisms involved in melanoma pathogenesis is crucial for improving diagnosis and therapy.

View Article and Find Full Text PDF

Individuals with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) have a high risk of developing other malignancies (OMs). The development of OMs may be associated with the advanced age of CLL/SLL patients, presence of a tumor-promoting microenvironment, immune alterations inherent to CLL/SLL, or chemotherapy. Importantly, the occurrence of OMs following frontline fludarabine, cyclophosphamide and rituximab (FCR) treatment is associated with a reduction in the overall survival (OS).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!